Trials / Not Yet Recruiting
Not Yet RecruitingNCT06649864
Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications
A Phase I Study of Autologous Adipose-derived Mesenchymal Stromal Cells in Preventing Biliary Complications After Living Donor Liver Transplant
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety of autologous Adipose-Derived Mesenchymal Stem Cell for use in End-Stage Liver Disease patients undergoing the creation of a duct-to-duct anastomosis during Living Donor Liver Transplantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Autologous adipose derived mesenchymal stromal cells (AMSC) | Adipose derived autologous mesenchymal stromal cells; \[\~500,000 cells/cm2\] will be applied once to the biliary anastomosis using approximately 3-5 million cells in 5ml Lactated Ringer solution. |
Timeline
- Start date
- 2027-02-01
- Primary completion
- 2028-01-01
- Completion
- 2028-06-01
- First posted
- 2024-10-21
- Last updated
- 2026-04-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06649864. Inclusion in this directory is not an endorsement.